
Zanidatamab Wins Approval in China for Previously Treated, HER2+ Biliary Tract Cancer
China’s National Medical Products Administration (NMPA) has granted conditional approval to zanidatamab-hrii (Ziihera) for the treatment of patients with previously treated, unresectable or metastatic, HER2-positive (immunohistochemistry [IHC] 3+) biliary …